Recently, a piece of exciting news has emerged: the polyacrylic acid solution (Registration No.: F20250000498) developed by Jiudian Hongyang as a pharmaceutical excipient has successfully obtained the registration certificate from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.​

Polyacrylic acid solution is a colorless or light yellow liquid, synthesized via the acrylic acid free radical polymerization process. As an anionic polymer, it possesses multiple functional properties such as thickening, gelation, and bioadhesion. In the pharmaceutical field, this product serves as a high-efficiency thickener and adhesive, and is widely applied in gel preparations, creams, and oral liquid preparations. By precisely adjusting the viscosity of formulations, it significantly improves the spreadability of external preparations or the palatability of oral liquid preparations. In sustained and controlled-release preparations, polyacrylic acid solution can form a gel barrier to achieve precise control over the drug release behavior, thereby enhancing the therapeutic effect and improving patient medication compliance. Notably, it also exhibits excellent scale inhibition and dispersion capabilities, which can effectively inhibit the microcrystalline deposition of calcium carbonate, calcium sulfate, and other substances. This characteristic endows it with important application value in maintaining the stability of liquid preparations.​

The successful registration of polyacrylic acid solution this time is not only an authoritative recognition of Jiudian Hongyang's technical strength and quality system, but also provides downstream customers with another reliable source of high-quality excipients. It will create more favorable conditions for Jiudian Hongyang to enter the high-end pharmaceutical excipient market.